Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2005 Raltegravir (MK-0518) <1 mg/mL 88 mg/mL <1 mg/mL
S2001 Elvitegravir (GS-9137, JTK-303) <1 mg/mL 89 mg/mL 35 mg/mL
S2667 Dolutegravir (GSK1349572) <1 mg/mL 83 mg/mL <1 mg/mL
S1366 BMS-707035 <1 mg/mL 38 mg/mL <1 mg/mL
S2765 MK-2048 <1 mg/mL 9 mg/mL <1 mg/mL
S5245 Raltegravir potassium <1 mg/mL 96 mg/mL 10 mg/mL
S7766 Cabotegravir (GSK744, GSK1265744) <1 mg/mL 38 mg/mL <1 mg/mL
S4642 Dolutegravir Sodium <1 mg/mL 0.2 mg/mL <1 mg/mL
S4187 Salicylanilide <1 mg/mL 43 mg/mL 18 mg/mL
Catalog No. Information Product Use Citations Product Validations

Raltegravir (MK-0518)

Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively. It shows greater than 1000-fold selectivity for HIV-1 IN over several related Mg2+-dependent enzyme such as HCV polymerase, HIV reverse transcriptase, HIV RNaseH and human α-, β-, γ-polymerases.


Elvitegravir (GS-9137, JTK-303)

Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.


Dolutegravir (GSK1349572)

Dolutegravir (GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.



BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2.



MK-2048 is a potent inhibitor of integrase (IN) and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively.


Raltegravir potassium

Raltegravir Potassium is the orally bioavailable potassium salt of raltegravir, the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor.


Cabotegravir (GSK744, GSK1265744)

Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.


Dolutegravir Sodium

Dolutegravir sodium is a HIV integrase inhibitor with IC50 of 2.7 nM.



Salicylanilides are a group of compounds with a wide range of biological activities including antiviral potency, antibacterial (including antimycobacterial) and antifungal activities.

Tags: Integrase activity | Integrase inhibitors mechanism | HIV Integrase inhibitor mechanism | Integrase assay | HIV Integrase assay | Integrase inhibitor drugs | HIV Integrase inhibitor drugs | Integrase inhibitor resistance testing | Integrase inhibitor review